<article id="dosing_wAMD" class="slide dosing" data-ag-name="Dosing wAMD">
  <div class="tab-title">wAMD</div>
  <h2 class="slide-title">ONCE EVERY 2 MONTHS DOSING<sup class="footnote-link">1</sup></h2>
    <div class="body-content">
      <div class="text">
        <h3 class="slide-subtitle">AFTER 3 INITIAL MONTHLY DOSES</h3>
        <p>The recommended dose of EYLEA<sup class="reg">&reg;</sup> for the treatment of wAMD is 2 mg (0.05 mL, or 50 ÂµL) administered by intravitreal injection:</p>
        <ul>
          <li>Monthly for 3 initial doses</li>
          <li>Followed by <strong>once every 2 months dosing</strong></li>
        </ul>
  
        <p><strong>After 12 months</strong>, the treatment interval could be extended up to <strong>once every 3 months</strong> based on visual and/or anatomic outcomes. Patients should be evaluated regularly.</p>
      </div>
      <img src="content_EN/img/badge.png" class="badge" />
    </div>
  <div class="chart-img"><img src="content_EN/img/charts_dosing-wamd.png" /></div>
</article>